ArticleNeuro-oncology2025
Intratumoral preservation of the stem-like malignant cell proportion in glioblastoma, prognostic impact, and its radiomethylomic signatures.
Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biology-informed risk stratification of glioblastoma by integrating MRI-based intratumoral heterogeneity with clinical features: a multicenter validation study.Experimental hematology & oncology · 2026Article
- Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) exhibits significant intratumoral heterogeneity. However, the presence and extent of intratumoral heterogeneity of stem-like and differentiated cell components based on methylation profiles remain poorly understood. Furthermore, the utility of integrating methylation profiles with radiomic features (radiomethylomics) for predicting these cellular states has not been explored.
methodsWe analyzed 248 samples from 133 GBM patients, including 157 samples from 42 patients whose tumors were sampled at multiple points. Two distinct methylation-based deconvolution analyses were performed to assess cellular composition. Radiomethylomic models were developed using support vector machines with features extracted from multi-parametric MRI.
resultsMulti-sampling analysis revealed that the proportion of stem-like cells among total malignant cells was homogeneously preserved within tumors. Tumors harboring a higher proportion of stem-like cells (stem-like tumors) showed significantly shorter overall survival and diminished benefits from O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Stem-like tumors showed a strong correlation with the RTK I subtype. Integrating physiological MRI features (diffusion tensor imaging and dynamic susceptibility contrast) with conventional sequences enhanced the performance of radiomethylomic models for predicting stem-like tumor status and prognostic stratification.
conclusionsOur findings reveal a homogeneous preservation of the proportion of stem-like cells over total malignant cells within GBM, establishing its significance as a tumor-wide feature. The development of radiomethylomic signatures shows potential for noninvasive assessment of tumor stemness, ultimately facilitating personalized treatment strategies in light of the prognostic impact of the feature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.